摘要
耐万古霉素肠球菌(vancomycin resistant enterococci,VRE)自1986年被发现以来,已逐渐发展成为世界范围内主要的院内感染病原菌,可导致菌血症、心内膜炎、腹盆腔感染、泌尿系感染、皮肤和皮肤结构感染及少见的中枢神经系统感染。尽管有新的药物问世,但VRE的治疗仍面临巨大临床挑战。了解VRE的流行病学、传播途径、定植和感染的危险因素是预防的关键。本文根据国内外相关文献报道,从VRE的流行病学、危险因素、耐药机制、药物治疗进展及感染控制策略等方面进行综述。
Since its discovery in 1986,vancomycin-resistant enterococcus （VRE） has increasingly become a major nosocomial pathogen worldwide.Typical clinical manifestations include bacteremia,endocarditis,intra-abdominal and pelvic infections,urinary tract infections,skin and skin structure infections,and,rarely,central nervous system infections.VRE infections continue to be a clinical challenge despite the advent of new therapeutic agents.Understanding VRE epidemiology,transmission and risk factors for colonization and infections are keys to its prevention.The epidemiology,risk factors,mechanism of action,advances of drug treatment of VRE and infection control strategies were reviewed in this article.
出处
《临床药物治疗杂志》
2017年第8期1-5,共5页
Clinical Medication Journal
关键词
肠球菌
万古霉素耐药
抗菌药物
治疗
enterococcus
vancomycin resistance
anti-bacterial agents
treatment
